Somaxon Pharmaceuticals (NASDAQ:SOMX) reports that its licensee, Paladin Labs, won the okay from Health Canada of the latter’s New Drug Submission for Silenor (doxepin), for the treatment and symptomatic relief of insomnia described as frequent nocturnal awakening and/or early morning awakenings.
Medifast (NYSE:MED) on Monday announced its increased international expansion intentions via a renewed strategic partnership with Productos Medix, which is a leader in pharmaceutical obesity products in Mexico. The former is a top domestic maker and supplier of clinically proven, portion-controlled weight-loss products and programs. Through a five-year exclusive licensing agreement, the firm plans to boost distribution of Medifast meal replacement products and programs to most of Latin America except Brazil, beginning in January.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Medtronic (NYSE:MDT) reports that one-year results from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation, have been published online prior to print in Circulation, the Journal of the American Heart Association. These data indicated that patients who initially received treatment with the Symplicity renal denervation system sustained a significant reduction in blood pressure (-28/-10 mm Hg [p<0.001]), as compared to baseline at 12 months. These 12 month results demonstrate preservation of the benefit at six month follow-up (-32/-12 mm Hg), and no late vascular complications, no device-related serious adverse events, nor significant decline in kidney function were reported at 12 months. However, the Symplicity renal denervation system is not approved by the FDA for domestic commercial distribution.
Pfizer’s (NYSE:PFE) board of directors has declared a 24-cent first quarter 2013 dividend on the firm’s common stock, payable March 5th, to shareholders of record at the close on February 1st. The company increased the dividend by approximately 9 percent, from 22 cents to 24 cents per share.
Don’t Miss: Does Qsymia Have a Future After All?